Foghorn Therapeutics Appoints Interim CFO Jeff Sacher

Tip Ranks
2025.12.04 12:31
portai
I'm PortAI, I can summarize articles.

Foghorn Therapeutics appointed Jeff Sacher as interim CFO on December 3, 2025, while searching for a permanent CFO. Sacher, with extensive biotechnology and investment banking experience, will provide services through Danforth Advisors. This appointment aims to bring strategic financial expertise during the transition. Analysts rate FHTX stock as a Buy with a $12.00 target, despite poor financial performance and high leverage. Foghorn Therapeutics focuses on innovative therapies in biotechnology.

TipRanks Cyber Monday Sale

  • Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

An update from Foghorn Therapeutics ( (FHTX) ) is now available.

On December 3, 2025, Foghorn Therapeutics appointed Jeff Sacher as Treasurer and interim CFO, while continuing its search for a permanent CFO. Mr. Sacher, a seasoned professional with extensive experience in biotechnology and investment banking, will provide interim CFO services through Danforth Advisors, a consultancy firm specializing in life sciences companies. This appointment is expected to bring strategic financial expertise to Foghorn Therapeutics during this transitional period.

The most recent analyst rating on (FHTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Foghorn Therapeutics stock, see the FHTX Stock Forecast page.

Spark’s Take on FHTX Stock

According to Spark, TipRanks’ AI Analyst, FHTX is a Neutral.

Foghorn Therapeutics’ overall stock score is primarily impacted by its poor financial performance, characterized by ongoing losses and high leverage. The technical analysis provides a slightly better outlook with some positive momentum indicators, but the valuation remains unattractive due to negative earnings. The absence of earnings call data and corporate events limits additional insights.

To see Spark’s full report on FHTX stock, click here.

More about Foghorn Therapeutics

Foghorn Therapeutics Inc. operates in the biotechnology industry, focusing on developing innovative therapies and solutions for various medical conditions.

Average Trading Volume: 205,222

Technical Sentiment Signal: Sell

Current Market Cap: $242.6M

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer